Drug Approval | January 23, 2023
Astellas announces hold lifted by FDA on Fortis clinical trial of AT845
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Following successful completion of full set of clinical studies of proposed rituximab biosimilar candidate DRL_RI, Dr. Reddy’s will now prepare to file in the United States, European Union and other regions
Connectivity and harmonisation were both key driving factors behind our decision to choose the CARA Life Sciences Platform to consolidate our processes
The goal is to bring oncology therapy closer to the communities by integrating all services such as chemotherapy and radiation centers
Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure
The company is excited about the strategic progress that the company has made so far and are confident of delivering better business outcomes
Sacu V is priced at Rs. 19 per tablet for a dose of 50 mg (sacubitril 24 mg + valsartan 26 mg)
Point-of-Care solution to facilitate clinicians in quick and effective decision making
Through the new agreements, Cristal Therapeutics and McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates
Monika and Prathmesh’s determination to participate in the Dream Run to increase awareness serves as a testament to life changing effects of organ transplants and importance of organ donation
Subscribe To Our Newsletter & Stay Updated
